title: Statins personalized.
abstract: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitor medications, commonly referred to as statins, are among the most widely prescribed medications. Variation in individual response to statins concerning low-density lipoprotein cholesterol reduction, clinical event benefit, and side effects has been observed. Some of this variability is attributed to demographic and environmental issues, chief of which is compliance. A large portion of the individual response to statin therapy is attributed to single nucleotide polymorphisms that have recently been elucidated, several of which seem to have clinical utility.
authors.affiliation: Celera Corporation, Alameda, CA 94502, USA. Robert.Superko@celera.com
authors.forename: H Robert
authors.initials: HR
authors.lastname: Superko
authors.forename: Kathryn M
authors.initials: KM
authors.lastname: Momary
authors.forename: Yonghong
authors.initials: Y
authors.lastname: Li
mesh_terms: D008078:Cholesterol, LDL / Q000378:metabolism; D004351:Drug Resistance / Q000235:genetics*; D050171:Dyslipidemias / Q000188:drug therapy* / Q000378:metabolism; D005544:Forecasting; D059647:Gene-Environment Interaction; D006801:Humans; D006903:Hydroxymethylglutaryl CoA Reductases / Q000235:genetics*; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000493:pharmacokinetics / Q000627:therapeutic use; D050356:Lipid Metabolism / Q000235:genetics*; D010349:Patient Compliance; D010597:Pharmacogenetics; D020641:Polymorphism, Single Nucleotide / Q000187:drug effects; D057285:Precision Medicine / Q000379:methods / Q000639:trends
chemical_list: D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D006903:Hydroxymethylglutaryl CoA Reductases